Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Anti-Infective Agents
Anti-Retroviral Agents
Contraceptive Usage

Interventions

DRUG: TFV/LNG IVR
DRUG: Placebo

Sponsor

CONRAD

Collaborators

[object Object]
[object Object]